8Q4U
 
 | |
8Q4Q
 | |
3E01
 | | HIV-RT with non-nucleoside inhibitor annulated pyrazole 2 | | Descriptor: | 3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile, Gag-Pol polyprotein | | Authors: | Harris, S.F, Villasenor, A. | | Deposit date: | 2008-07-30 | | Release date: | 2008-11-25 | | Last modified: | 2024-02-21 | | Method: | X-RAY DIFFRACTION (2.95 Å) | | Cite: | Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase
J.Med.Chem., 51, 2008
|
|
1YQC
 | | Crystal Structure of Ureidoglycolate Hydrolase (AllA) from Escherichia coli O157:H7 | | Descriptor: | GLYOXYLIC ACID, Ureidoglycolate hydrolase | | Authors: | Raymond, S, Tocilj, A, Matte, A, Cygler, M, Montreal-Kingston Bacterial Structural Genomics Initiative (BSGI) | | Deposit date: | 2005-02-01 | | Release date: | 2005-10-18 | | Last modified: | 2017-10-11 | | Method: | X-RAY DIFFRACTION (1.709 Å) | | Cite: | Crystal structure of ureidoglycolate hydrolase (AllA) from Escherichia coli O157:H7
Proteins, 61, 2005
|
|
7DAC
 | | Human RIPK3 amyloid fibril revealed by solid-state NMR | | Descriptor: | Receptor-interacting serine/threonine-protein kinase 3 | | Authors: | Wu, X.L, Zhang, J, Dong, X.Q, Liu, J, Li, B, Hu, H, Wang, J, Wang, H.Y, Lu, J.X. | | Deposit date: | 2020-10-16 | | Release date: | 2021-04-28 | | Last modified: | 2024-05-01 | | Method: | SOLID-STATE NMR | | Cite: | The structure of a minimum amyloid fibril core formed by necroptosis-mediating RHIM of human RIPK3.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
7DA4
 | | Cryo-EM structure of amyloid fibril formed by human RIPK3 | | Descriptor: | Receptor-interacting serine/threonine-protein kinase 3 | | Authors: | Zhao, K, Ma, Y.Y, Sun, Y.P, Li, D, Liu, C. | | Deposit date: | 2020-10-14 | | Release date: | 2021-04-28 | | Last modified: | 2024-03-27 | | Method: | ELECTRON MICROSCOPY (4.24 Å) | | Cite: | The structure of a minimum amyloid fibril core formed by necroptosis-mediating RHIM of human RIPK3.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
3DY7
 | | X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP | | Descriptor: | (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide, ADENOSINE-5'-TRIPHOSPHATE, Dual specificity mitogen-activated protein kinase kinase 1, ... | | Authors: | Ohren, J.F, Pavlovsky, A, Zhang, E. | | Deposit date: | 2008-07-25 | | Release date: | 2009-06-16 | | Last modified: | 2023-08-30 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?
Bioorg.Med.Chem.Lett., 19, 2009
|
|
3DYA
 | | HIV-1 RT with non-nucleoside inhibitor annulated Pyrazole 1 | | Descriptor: | 3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile, REVERSE TRANSCRIPTASE/RIBONUCLEASE H, p51 RT | | Authors: | Harris, S.F, Villasenor, A. | | Deposit date: | 2008-07-25 | | Release date: | 2008-11-25 | | Last modified: | 2024-02-21 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase
J.Med.Chem., 51, 2008
|
|
8Q2T
 | |
8Q33
 | | Crystal structure of YTHDC1 in complex with Compound 15 (ZA_343) | | Descriptor: | SULFATE ION, YTH domain-containing protein 1, ~{N}-[2-[[2-chloranyl-6-(methylamino)purin-9-yl]methyl]phenyl]-2,2,2-tris(fluoranyl)ethanamide | | Authors: | Bedi, R.K, Zalesak, F, Caflisch, A. | | Deposit date: | 2023-08-03 | | Release date: | 2023-12-06 | | Last modified: | 2024-06-19 | | Method: | X-RAY DIFFRACTION (1.43 Å) | | Cite: | Structure-Based Design of a Potent and Selective YTHDC1 Ligand.
J.Med.Chem., 67, 2024
|
|
8Q4R
 | |
8Q4V
 | | Crystal structure of YTHDC1 in complex with Compound 37 (ZA_356) | | Descriptor: | 2-chloranyl-9-[(3-chlorophenyl)methyl]-~{N}-cyclopropyl-7,8-dihydropurin-6-amine, SULFATE ION, YTH domain-containing protein 1 | | Authors: | Bedi, R.K, Zalesak, F, Caflisch, A. | | Deposit date: | 2023-08-07 | | Release date: | 2023-12-06 | | Last modified: | 2024-06-19 | | Method: | X-RAY DIFFRACTION (1.36 Å) | | Cite: | Structure-Based Design of a Potent and Selective YTHDC1 Ligand.
J.Med.Chem., 67, 2024
|
|
8Q31
 | |
8Q4P
 | |
8Q2Y
 | |
8Q3G
 | |
8Q4W
 | | Crystal structure of YTHDC1 in complex with Compound 40 (CS_3a) | | Descriptor: | 5-chloranyl-3-[(3-chlorophenyl)methyl]-~{N}-methyl-2~{H}-pyrazolo[4,3-d]pyrimidin-7-amine, SULFATE ION, YTH domain-containing protein 1 | | Authors: | Bedi, R.K, Zalesak, F, Caflisch, A. | | Deposit date: | 2023-08-07 | | Release date: | 2023-12-06 | | Last modified: | 2024-06-19 | | Method: | X-RAY DIFFRACTION (1.61 Å) | | Cite: | Structure-Based Design of a Potent and Selective YTHDC1 Ligand.
J.Med.Chem., 67, 2024
|
|
8Q2X
 | |
8Q3A
 | |
8Q4N
 | |
8Q2S
 | |
8Q35
 | |
8Q2V
 | |
8Q39
 | | Crystal structure of YTHDC1 in complex with Compound 21 (ZA_515) | | Descriptor: | 2-chloranyl-N-methyl-9-[[3-(1H-1,2,3,4-tetrazol-5-yl)phenyl]methyl]purin-6-amine, SULFATE ION, YTH domain-containing protein 1 | | Authors: | Bedi, R.K, Zalesak, F, Caflisch, A. | | Deposit date: | 2023-08-03 | | Release date: | 2023-12-06 | | Last modified: | 2024-06-19 | | Method: | X-RAY DIFFRACTION (1.42 Å) | | Cite: | Structure-Based Design of a Potent and Selective YTHDC1 Ligand.
J.Med.Chem., 67, 2024
|
|
8Q4T
 | |
